KRYS News and Press, Krystal Biotech Inc. From 04/02/22

The following slide deck was published by Krystal Biotech, Inc. in conjunction with this event. For further details see: Krystal Biotech (KRYS) AAD GEM-3 Phase 3 Data Presentation - Slideshow

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared wi...

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . , (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an ...

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy ...

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022 American Academy of Dermatology Annual M...

Krystal Biotech (NASDAQ:KRYS) said it reached an agreement with PeriphaGen to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020. Under the conditions of the term sheet, Krystal will receive all of PeriphaGen’s biological materials and skin asset...

PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. (“PeriphaGen”) to resolve al...

Krystal Biotech press release (NASDAQ:KRYS): Q4 GAAP EPS of -$3.13 misses by $2.40. Cash, cash equivalents and investments totaled $502.5 million on December 31, 2021, compared to $271.3 million as of December 31, 2020. The increase of $231.2 million is inclusive of net pr...

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022 Phase 1 trial of KB407 in cystic fibrosis patients in Australia expe...